New Data Demonstrates Significant Advantage in Mortality, Hospitalization, and Patient Dropout with NxStage Home Hemodialysis when Compared with Peritoneal Dialysis

LAWRENCE, Mass., Nov. 11, 2014 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM) today announced that a new study conducted by the Chronic Disease Research Group (CDRG) will be presented orally and in a poster session at the American Society of Nephrology's Kidney Week 2014, November 11 - 16 in Philadelphia, Pennsylvania by Eric Weinhandl, MS, PhD candidate, and epidemiologist at the CDRG. The results of the first matched cohort study of its kind show frequent home hemodialysis (HHD) patients have a 16% lower risk of death, 8% lower risk of hospitalization, and 38% lower risk of therapy attrition than peritoneal dialysis (PD) patients.

Using a 33-factor algorithm to match 4,460 frequent HHD patients with 4,460 PD patients, the results of the study showed that there was 13% lower risk of cardiovascular-related death and 20% lower risk of infection-related death with HHD therapy.  Additionally, frequent HHD patients were 16% and 11% less likely to be hospitalized for cardiovascular or infection-related diagnoses, respectively.

"This study provides evidence that HHD is not only a viable alternative to PD, but may be a better alternative for some patients electing to perform home dialysis," said Weinhandl. "Moreover, the study challenges the commonly held conception that therapy attrition is higher with HHD than with PD."

In addition to CDRG findings, the FREEDOM Study, a research project funded by NxStage, showed frequent home hemodialysis treatment for ESRD patients is associated with a more positive and sustained impact on quality of life than patients' prior therapies. Together, these findings show that improved survival, better hospitalization rate, and longer therapy retention on HHD therapy may translate to a patient's perception of their overall quality of life and general well-being.

"Our patients constantly tell us that home hemodialysis with the NxStage System One has significantly changed their lives for the better," said NxStage President, Joseph Turk. "These findings present a compelling reason to further strengthen HHD programs and expand patient access to this life changing therapy."

Published abstracts and program details are available on the ASN Kidney Week website.

Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the FDA. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation. http://www.nxstage.com/.

About NxStage Medical, Inc.  
NxStage is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact: 
Kristen K. Sheppard, Esq.
[email protected]

Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO

SOURCE NxStage Medical, Inc.

Related Links

http://www.nxstage.com